NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B74710126) describing the safety and immunogenicity of PREVNAR 20â„¢ (Pneumococcal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback